Clinical Trial Update: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM [Phase 2]

View source ↗

Summary

Phase II trial evaluating NGR-hTNF vs placebo as maintenance in advanced malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Advanced Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED